source
- Madrigal secures fourth MASH partnership, snapping up Arrowhead drug passed over by J&JMadrigal Pharmaceuticals announced its latest collaboration, marking the fourth deal focused on metabolic dysfunction-associated steatohepatitis (MASH) within a ten‑month span. The agreement bring…
- Emerging Antibody-Drug Conjugates Target New Endometrial Cancer Antigens Beyond HER2Faculty members highlighted a growing interest in endometrial cancer therapies that go beyond the HER2 pathway. They noted that the field is expanding its focus to a broader set of molecular target…